TI
CLDX icon

Telemetry Investments’s Celldex Therapeutics CLDX Stock Holding History

Telemetry Investments’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-23,233
Closed -$69K – 104
2018
Q4 		$69K Buy
23,233
+10,820
+87% +$53.1K 0.04% 128
2018
Q3 		$84K Sell
12,413
-4,407
-26% -$30.9K 0.04% 113
2018
Q2 		$127K Buy
+16,820
New +$225K 0.05% 122
2016
Q1 		– Sell
-1,600
Closed -$376K – 107
2015
Q4 		$376K Buy
+1,600
New +$349K 0.13% 89

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Telemetry Investments's CLDX Position: Q1 2019 in Review

Telemetry Investments sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 23,233 shares — an estimated $69K sold.

Telemetry Investments first reported a position in CLDX in Q4 2015 and held it in 4 quarters. The position peaked at $376K in Q4 2015. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • Telemetry Investments reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Telemetry Investments sold 23,233 Celldex Therapeutics shares in Q1 2019, an estimated $69K.
  • Telemetry Investments first reported a position in Celldex Therapeutics in Q4 2015 and held it in 4 quarters.
  • Telemetry Investments's Celldex Therapeutics position peaked at $376K in Q4 2015.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on Telemetry Investments's 13F filing for Q1 2019, filed 15 May 2019.